Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Several recent trials have shown a significant overall survival (OS) benefit from postoperative cisplatin-based chemotherapy in patients with non-small-cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy.Individual patient data were collected and pooled from the five largest...